KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Abbott Laboratories (ABT) Enterprise Value (2016 - 2026)

Abbott Laboratories' Enterprise Value history spans 18 years, with the latest figure at -$6.7 billion for Q1 2026.

  • On a quarterly basis, Enterprise Value fell 0.97% to -$6.7 billion in Q1 2026 year-over-year; TTM through Mar 2026 was -$6.7 billion, a 0.97% decrease, with the full-year FY2025 number at -$8.3 billion, down 7.35% from a year prior.
  • Enterprise Value hit -$6.7 billion in Q1 2026 for Abbott Laboratories, up from -$8.3 billion in the prior quarter.
  • Over the last five years, Enterprise Value for ABT hit a ceiling of -$6.4 billion in Q1 2024 and a floor of -$10.0 billion in Q4 2022.
  • Historically, Enterprise Value has averaged -$7.8 billion across 5 years, with a median of -$7.6 billion in 2024.
  • Biggest five-year swings in Enterprise Value: dropped 17.43% in 2023 and later surged 31.06% in 2024.
  • Tracing ABT's Enterprise Value over 5 years: stood at -$10.0 billion in 2022, then grew by 29.1% to -$7.1 billion in 2023, then fell by 9.57% to -$7.7 billion in 2024, then decreased by 7.35% to -$8.3 billion in 2025, then rose by 19.8% to -$6.7 billion in 2026.
  • Business Quant data shows Enterprise Value for ABT at -$6.7 billion in Q1 2026, -$8.3 billion in Q4 2025, and -$7.4 billion in Q3 2025.